Stock data
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS) reported revenue of US$244.06M and net income of US$87.01M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$244.06M | — | US$67.57M | US$87.01M | — |
| 2024 | US$3.55M | — | -US$210.83M | -US$187.35M | — |
| 2023 | US$0.15M | — | -US$169.94M | -US$152.99M | — |
| 2022 | US$0.00M | — | -US$114.79M | -US$104.68M | — |
| 2021 | US$20.10M | — | -US$56.37M | -US$58.74M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$28.71M | — |
| 2026-03-31 | US$0.37M | -US$23.71M | — |
| 2025-12-31 | US$0.39M | -US$23.46M | — |
| 2025-09-30 | US$14.26M | -US$7.28M | — |
| 2025-06-30 | US$18.17M | -US$30.70M | — |
| 2025-03-31 | US$211.25M | US$148.45M | — |
| 2024-12-31 | US$3.04M | -US$46.03M | — |
| 2024-09-30 | US$0.39M | -US$52.96M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.